Proficio Capital Partners LLC raised its position in shares of GlaxoSmithKline PLC (NYSE:GSK) by 16.1% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 3,301 shares of the pharmaceutical company’s stock after buying an additional 457 shares during the period. Proficio Capital Partners LLC’s holdings in GlaxoSmithKline PLC were worth $135,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Bronfman E.L. Rothschild L.P. boosted its stake in shares of GlaxoSmithKline PLC by 45.4% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 2,410 shares of the pharmaceutical company’s stock worth $102,000 after buying an additional 753 shares during the last quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC boosted its stake in shares of GlaxoSmithKline PLC by 1,747.4% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 2,494 shares of the pharmaceutical company’s stock worth $105,000 after buying an additional 2,359 shares during the last quarter. Heritage Trust Co acquired a new stake in shares of GlaxoSmithKline PLC during the first quarter worth approximately $123,000. Westwood Holdings Group Inc. boosted its stake in shares of GlaxoSmithKline PLC by 15.7% in the first quarter. Westwood Holdings Group Inc. now owns 2,950 shares of the pharmaceutical company’s stock worth $124,000 after buying an additional 400 shares during the last quarter. Finally, Advisory Services Network LLC acquired a new stake in shares of GlaxoSmithKline PLC during the first quarter worth approximately $137,000. 8.99% of the stock is currently owned by hedge funds and other institutional investors.

GlaxoSmithKline PLC (NYSE GSK) opened at 38.75 on Friday. GlaxoSmithKline PLC has a one year low of $37.20 and a one year high of $44.54. The stock’s 50 day moving average is $41.15 and its 200 day moving average is $41.84. The stock has a market capitalization of $94.71 billion, a price-to-earnings ratio of 38.06 and a beta of 1.03.

GlaxoSmithKline PLC (NYSE:GSK) last released its earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.68 by $0.02. GlaxoSmithKline PLC had a return on equity of 114.93% and a net margin of 6.48%. The company had revenue of $9.36 billion for the quarter, compared to analysts’ expectations of $9.52 billion. On average, equities analysts forecast that GlaxoSmithKline PLC will post $2.85 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 12th. Shareholders of record on Friday, August 11th will be paid a dividend of $0.491 per share. This represents a $1.96 annualized dividend and a yield of 5.07%. The ex-dividend date is Wednesday, August 9th. This is a boost from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. GlaxoSmithKline PLC’s payout ratio is 197.00%.

ILLEGAL ACTIVITY WARNING: This report was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.thecerbatgem.com/2017/08/20/proficio-capital-partners-llc-increases-position-in-glaxosmithkline-plc-gsk.html.

A number of equities research analysts recently commented on the stock. Citigroup Inc. reissued a “neutral” rating on shares of GlaxoSmithKline PLC in a research note on Thursday, July 27th. J P Morgan Chase & Co reissued a “neutral” rating on shares of GlaxoSmithKline PLC in a research note on Wednesday, May 31st. TheStreet cut shares of GlaxoSmithKline PLC from a “b” rating to a “c+” rating in a research note on Wednesday, July 26th. Zacks Investment Research raised shares of GlaxoSmithKline PLC from a “hold” rating to a “buy” rating and set a $47.00 price objective on the stock in a research note on Tuesday, July 18th. Finally, Berenberg Bank raised shares of GlaxoSmithKline PLC from a “hold” rating to a “buy” rating in a research note on Friday, May 26th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and nine have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $44.67.

About GlaxoSmithKline PLC

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline PLC (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Stock Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related stocks with our FREE daily email newsletter.